These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

361 related items for PubMed ID: 16309167

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Osteoprotegerin overexpression by breast cancer cells enhances orthotopic and osseous tumor growth and contrasts with that delivered therapeutically.
    Fisher JL, Thomas-Mudge RJ, Elliott J, Hards DK, Sims NA, Slavin J, Martin TJ, Gillespie MT.
    Cancer Res; 2006 Apr 01; 66(7):3620-8. PubMed ID: 16585187
    [Abstract] [Full Text] [Related]

  • 3. Human bone marrow stromal cells protect prostate cancer cells from TRAIL-induced apoptosis.
    Nyambo R, Cross N, Lippitt J, Holen I, Bryden G, Hamdy FC, Eaton CL.
    J Bone Miner Res; 2004 Oct 01; 19(10):1712-21. PubMed ID: 15355567
    [Abstract] [Full Text] [Related]

  • 4. Lipopolysaccharide stimulates expression of osteoprotegerin and receptor activator of NF-kappa B ligand in periodontal ligament fibroblasts through the induction of interleukin-1 beta and tumor necrosis factor-alpha.
    Wada N, Maeda H, Yoshimine Y, Akamine A.
    Bone; 2004 Sep 01; 35(3):629-35. PubMed ID: 15336598
    [Abstract] [Full Text] [Related]

  • 5. Osteoprotegerin is a soluble decoy receptor for tumor necrosis factor-related apoptosis-inducing ligand/Apo2 ligand and can function as a paracrine survival factor for human myeloma cells.
    Shipman CM, Croucher PI.
    Cancer Res; 2003 Mar 01; 63(5):912-6. PubMed ID: 12615702
    [Abstract] [Full Text] [Related]

  • 6. Sensitivity of prostate cells to TRAIL-induced apoptosis increases with tumor progression: DR5 and caspase 8 are key players.
    Hesry V, Piquet-Pellorce C, Travert M, Donaghy L, Jégou B, Patard JJ, Guillaudeux T.
    Prostate; 2006 Jun 15; 66(9):987-95. PubMed ID: 16541419
    [Abstract] [Full Text] [Related]

  • 7. Down-regulation of osteoprotegerin production in bone marrow macrophages by macrophage colony-stimulating factor.
    Yamada N, Tsujimura T, Ueda H, Hayashi S, Ohyama H, Okamura H, Terada N.
    Cytokine; 2005 Aug 21; 31(4):288-97. PubMed ID: 15996478
    [Abstract] [Full Text] [Related]

  • 8. Osteoprotegerin (OPG) is a survival factor for human prostate cancer cells.
    Holen I, Croucher PI, Hamdy FC, Eaton CL.
    Cancer Res; 2002 Mar 15; 62(6):1619-23. PubMed ID: 11912131
    [Abstract] [Full Text] [Related]

  • 9. Detection and characterization of RANK ligand and osteoprotegerin in the thyroid gland.
    Hofbauer LC, Kluger S, Kühne CA, Dunstan CR, Burchert A, Schoppet M, Zielke A, Heufelder AE.
    J Cell Biochem; 2002 Mar 15; 86(4):642-50. PubMed ID: 12210731
    [Abstract] [Full Text] [Related]

  • 10. Skeletal changes in osteoprotegerin and receptor activator of nuclear factor-kappab ligand mRNA levels in primary hyperparathyroidism: effect of parathyroidectomy and association with bone metabolism.
    Stilgren LS, Rettmer E, Eriksen EF, Hegedüs L, Beck-Nielsen H, Abrahamsen B.
    Bone; 2004 Jul 15; 35(1):256-65. PubMed ID: 15207766
    [Abstract] [Full Text] [Related]

  • 11. [Effects of 1,25-dihydroxyvitamin D3 on the expressions of osteoprotegerin and receptor activator of NF-kappaB ligand in mouse osteoblasts].
    Tian QX, Huang GY.
    Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2004 Aug 15; 26(4):418-22. PubMed ID: 15379268
    [Abstract] [Full Text] [Related]

  • 12. Expression of receptor activator of nuclear factor kappabeta ligand (RANKL) and tumour necrosis factor related, apoptosis inducing ligand (TRAIL) in breast cancer, and their relations with osteoprotegerin, oestrogen receptor, and clinicopathological variables.
    Cross SS, Harrison RF, Balasubramanian SP, Lippitt JM, Evans CA, Reed MW, Holen I.
    J Clin Pathol; 2006 Jul 15; 59(7):716-20. PubMed ID: 16489180
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Expression and functional activity of osteoprotegerin in human malignant gliomas.
    Naumann U, Wick W, Beschorner R, Meyermann R, Weller M.
    Acta Neuropathol; 2004 Jan 15; 107(1):17-22. PubMed ID: 14504888
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Role of the RANKL/RANK system in the induction of interleukin-8 (IL-8) in B chronic lymphocytic leukemia (B-CLL) cells.
    Secchiero P, Corallini F, Barbarotto E, Melloni E, di Iasio MG, Tiribelli M, Zauli G.
    J Cell Physiol; 2006 Apr 15; 207(1):158-64. PubMed ID: 16270354
    [Abstract] [Full Text] [Related]

  • 19. Osteoprotegerin secretion from prostate cancer is stimulated by cytokines, in vitro.
    Penno H, Silfverswärd CJ, Frost A, Brändström H, Nilsson O, Ljunggren O.
    Biochem Biophys Res Commun; 2002 Apr 26; 293(1):451-5. PubMed ID: 12054622
    [Abstract] [Full Text] [Related]

  • 20. Anti-tumor necrosis factor therapy increases synovial osteoprotegerin expression in rheumatoid arthritis.
    Catrina AI, af Klint E, Ernestam S, Catrina SB, Makrygiannakis D, Botusan IR, Klareskog L, Ulfgren AK.
    Arthritis Rheum; 2006 Jan 26; 54(1):76-81. PubMed ID: 16385498
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 19.